Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 1058-1069

  Sissung, Tristan M ^a   Thordardottir, Silja ^b   Gardner, Erin R ^c   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c SAIC FREDERICK INC   (United States)

Author keywords

Angiogenesis inhibition; CC 5013; Lenalidomide; Prostate cancer; Thalidomide

Indexed keywords

BEVACIZUMAB; CYCLOOXYGENASE 2; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; LEUPRORELIN; PLACEBO; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CHIRALITY; CLINICAL TRIAL; CONSTIPATION; DEGRADATION; DIZZINESS; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FATIGUE; GENE INACTIVATION; HUMAN; HYDROLYSIS; IMMUNOMODULATION; JAW OSTEONECROSIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; METASTASIS POTENTIAL; MOOD DISORDER; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SURVIVAL TIME; THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; MALE; METABOLISM; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 73349134659     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789735017     Document Type: Review

References (95)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics:2008. CA Cancer J. Clin., 2008, 58(2), 71-96.
2. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004, 351(15), 1513-20.
3. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberger, M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351(15), 1502-12.
4. Lenz, W.; Pfeiffer, R.; Kosenow, W.; Hayman, D. Thalidomide and congenital abnormalities. Lancet, 1962, 27945-46.
5. McBride, W. Thalidomide and congenital abnormalities. Lancet, 1961, 2781358.
6. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther., 1965, 6303-6.
7. Sampaio, E.P.; Sarno, E.N.; Galilly, R.; Cohn, Z.A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 1991, 173(3), 699-703.
8. Knobloch, J.; Shaughnessy, J.D., Jr.; Ruther, U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J., 2007, 21(7), 1410-21.
9. Hansen, J.M.; Harris, C. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid. Redox Signal, 2004, 6(1), 1-14.
10. Therapontos, C.; Erskine, L.; Gardner, E.R.; Figg, W.D.; Vargesson, N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. USA 2009, 106(21), 8573-8.
11. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91(9), 4082-5.
12. Aragon-Ching, J.B.; Li, H.; Gardner, E.R.; Figg, W.D. Thalidomide analogues as anticancer drugs. Recent Pat. Anticancer Drug Discov., 2007, 2(2), 167-74.
13. Bamias, A.; Dimopoulos, M.A. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin. Investig. Drugs, 2005, 14(1), 45-55.
14. Haverkamp, J.; Charbonneau, B.; Ratliff, T.L. Prostate inflammation and its potential impact on prostate cancer: a current review. J. Cell Biochem., 2008, 103(5), 1344-53.
15. Heinrich, P.C.; Behrmann, I.; Haan, S.; Hermanns, H.M.; Muller-Newen, G.; Schaper, F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J., 2003, 374(Pt 1), 1-20.
16. Ko, S.; Shi, L.; Kim, S.; Song, C.S.; Chatterjee, B. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol. Endocrinol., 2008, 22(2), 273-86.
17. Maxwell, P.J.; Gallagher, R.; Seaton, A.; Wilson, C.; Scullin, P.; Pettigrew, J.; Stratford, I.J.; Williams, K.J.; Johnston, P.G.; Waugh, D.J. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene, 2007, 26(52), 7333-45.
18. Royuela, M.; Rodriguez-Berriguete, G.; Fraile, B.; Paniagua, R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol. Histopathol., 2008, 23(10), 1279-90.
19. Daniel, T.O.; Liu, H.; Morrow, J.D.; Crews, B.C.; Marnett, L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res., 1999, 59(18), 4574-7.
20. Macpherson, G.R.; Franks, M.; Tomoaia-Cotisel, A.; Ando, Y.; Price, D.K.; Figg, W.D. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit. Rev. Oncol. Hematol., 2003, 46 (Suppl), S49-57.
21. Ng, S.S.; MacPherson, G.R.; Gutschow, M.; Eger, K.; Figg, W.D. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin. Cancer Res., 2004, 10(12 Pt 1), 4192-7.
22. Balkwill, F. Tumor necrosis factor or tumor promoting factor? Cytokine. Growth Factor Rev., 2002, 13(2), 135-41.
23. Michalaki, V.; Syrigos, K.; Charles, P.; Waxman, J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer, 2004, 90(12), 2312-6.
24. Wise, G.J.; Marella, V.K.; Talluri, G.; Shirazian, D. Cytokine variations in patients with hormone treated prostate cancer. J. Urol., 2000, 164(3 Pt 1), 722-5.
25. Li, S.P.; Meng, S.Y.; Li, R. Clinical evaluation of four cytokines in serum and prostatic fluid in chronic abacterial prostatitis. Zhonghua Nan Ke Xue, 2006, 12(1), 25-7.
26. Perambakam, S.M.; Srivastava, R.; Peace, D.J. Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin. Immunol., 2005, 117(1), 94-9.
27. Pfitzenmaier, J.; Vessella, R.; Higano, C.S.; Noteboom, J.L.; Wallace, D., Jr.; Corey, E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer, 2003, 97(5), 1211-6.
28. Efstathiou, E.; Troncoso, P.; Wen, S.; Do, K.A.; Pettaway, C.A.; Pisters, L.L.; McDonnell, T.J.; Logothetis, C.J. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin. Cancer Res., 2007, 13(4), 1224-31.
29. Figg, W.D.; Dahut, W.; Duray, P.; Hamilton, M.; Tompkins, A.; Steinberg, S.M.; Jones, E.; Premkumar, A.; Linehan, W.M.; Floeter, M.K.; Chen, C.C.; Dixon, S.; Kohler, D.R.; Kruger, E.A.; Gubish, E.; Pluda, J.M.; Reed, E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res., 2001, 7(7), 1888-93.
30. Leonard, G.D.; Dahut, W.L.; Gulley, J.L.; Arlen, P.M.; Figg, W.D. Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Rev. Urol., 2003, 5(Suppl), 3S65-70.
31. Kurokouchi, K.; Kambe, F.; Yasukawa, K.; Izumi, R.; Ishiguro, N.; Iwata, H.; Seo, H. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J. Bone Miner. Res., 1998, 13(8), 1290-9.
32. Culig, Z.; Steiner, H.; Bartsch, G.; Hobisch, A. Interleukin-6 regulation of prostate cancer cell growth. J. Cell Biochem., 2005, 95(3), 497-505.
33. Stark, J.R.; Li, H.; Kraft, P.; Kurth, T.; Giovannucci, E.L.; Stampfer, M.J.; Ma, J.; Mucci, L.A. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int. J. Cancer, 2009, 124(11), 2683-9.
34. Rowland, T.L.; McHugh, S.M.; Deighton, J.; Dearman, R.J.; Ewan, P.W.; Kimber, I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology, 1998, 40(1), 11-20.
35. Inoue, K.; Slaton, J.W.; Eve, B.Y.; Kim, S.J.; Perrotte, P.; Balbay, M.D.; Yano, S.; Bar-Eli, M.; Radinsky, R.; Pettaway, C.A.; Dinney, C.P. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res., 2000, 6(5), 2104-19.
36. Uehara, H.; Troncoso, P.; Johnston, D.; Bucana, C.D.; Dinney, C.; Dong, Z.; Fidler, I.J.; Pettaway, C.A. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate, 2005, 64(1), 40-9.
37. Wang, J.M.; Taraboletti, G.; Matsushima, K.; Van Damme, J.; Mantovani, A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem. Biophys. Res. Commun., 1990, 169(1), 165-70.
38. Mercurio, F.; Manning, A.M. Multiple signals converging on NF-kappaB. Curr. Opin. Cell Biol., 1999, 11(2), 226-32.
39. Keifer, J.A.; Guttridge, D.C.; Ashburner, B.P.; Baldwin, A.S., Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem., 2001, 276(25), 22382-7.
40. Muenchen, H.J.; Lin, D.L.; Walsh, M.A.; Keller, E.T.; Pienta, K.J. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaB-alpha "super- repressor". Clin. Cancer Res., 2000, 6(5), 1969-77.
41. Sunderkotter, C.; Steinbrink, K.; Goebeler, M.; Bhardwaj, R.; Sorg, C. Macrophages and angiogenesis. J. Leukoc. Biol., 1994, 55(3), 410-22.
42. Dahut, W.L.; Gulley, J.L.; Arlen, P.M.; Liu, Y.; Fedenko, K.M.; Steinberg, S.M.; Wright, J.J.; Parnes, H.; Chen, C.C.; Jones, E.; Parker, C.E.; Linehan, W.M.; Figg, W.D. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol., 2004, 22(13), 2532-9.
43. Figg, W.D.; Li, H.; Sissung, T.; Retter, A.; Wu, S.; Gulley, J.L.; Arlen, P.; Wright, J.J.; Parnes, H.; Fedenko, K.; Latham, L.; Steinberg, S.M.; Jones, E.; Chen, C.; Dahut, W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int., 2007, 99(5), 1047-55.
44. Kirschenbaum, A.; Liu, X.; Yao, S.; Levine, A.C. The role of cyclooxygenase-2 in prostate cancer. Urology, 2001, 58(2 Suppl 1), 127-31.
45. Fujita, J.; Mestre, J.R.; Zeldis, J.B.; Subbaramaiah, K.; Dannenberg, A.J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin. Cancer Res., 2001, 7(11), 3349-55.
46. Jin, S.H.; Kim, T.I.; Yang, K.M.; Kim, W.H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur. J. Pharmacol., 2007, 558(1-3), 14-20.
47. Warfel, N.A.; Lepper, E.R.; Zhang, C.; Figg, W.D.; Dennis, P.A. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin. Cancer Res., 2006, 12(11 Pt 1), 3502-9.
48. Smyth, M.J.; Hayakawa, Y.; Takeda, K.; Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer, 2002, 2(11), 850-61.
49. Gannon, P.O.; Poisson, A.O.; Delvoye, N.; Lapointe, R.; Mes-Masson, A.M.; Saad, F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods., 2009, 348(1-2), 9-17.
50. Galustian, C.; Dalgleish, A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin. Pharmacother., 2009, 10(1), 125-33.
51. Wang, W.; Bergh, A.; Damber, J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate, 2004, 61(1), 60-72.
52. Weidner, N.; Carroll, P.R.; Flax, J.; Blumenfeld, W.; Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 1993, 143(2), 401-9.
53. Siegal, J.A.; Yu, E.; Brawer, M.K. Topography of neovascularity in human prostate carcinoma. Cancer, 1995, 75(10), 2545-51.
54. Aragon-Ching, J.B.; Dahut, W.L. The role of angiogenesis inhibitors in prostate cancer. Cancer J., 2008, 14(1), 20-5.
55. Joseph, I.B.; Isaacs, J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst., 1998, 90(21), 1648-53.
56. Kenyon, B.M.; Browne, F.; D'Amato, R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res., 1997, 64(6), 971-8.
57. Vacca, A.; Scavelli, C.; Montefusco, V.; Di Pietro, G.; Neri, A.; Mattioli, M.; Bicciato, S.; Nico, B.; Ribatti, D.; Dammacco, F.; Corradini, P. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J. Clin. Oncol., 2005, 23(23), 5334-46.
58. Lepper, E.R.; Smith, N.F.; Cox, M.C.; Scripture, C.D.; Figg, W.D. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr. Drug Metab., 2006, 7(6), 677-85.
59. Yabu, T.; Tomimoto, H.; Taguchi, Y.; Yamaoka, S.; Igarashi, Y.; Okazaki, T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood, 2005, 106(1), 125-34.
60. Li, H.; Raia, V.; Bertolini, F.; Price, D.K.; Figg, W.D. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU. Int., 2008, 101(7), 884-8.
61. Fujita, K.; Asami, Y.; Murata, E.; Akita, M.; Kaneko, K. Effects of thalidomide, cytochrome P-450 and TNF-alpha on angiogenesis in a three-dimensional collagen gel-culture. Okajimas. Folia. Anat. Jpn., 2002, 79(4), 101-6.
62. De, A.K.; Kodys, K.; Puyana, J.C.; Fudem, G.; Savoie, P.; Miller-Graziano, C.L. Elevated IL-8 production by trauma patients' monocytes is associated with elevated secretion of TNF alpha. Shock, 1995, 4(3), 171-7.
63. Ferrer, F.A.; Miller, L.J.; Andrawis, R.I.; Kurtzman, S.H.; Albertsen, P.C.; Laudone, V.P.; Kreutzer, D.L. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51(1), 161-7.
64. Wilmer, J.L.; Luster, M.I. Chemical induction of interleukin-8, a proinflammatory chemokine, in human epidermal keratinocyte cultures and its relation to cytogenetic toxicity. Cell Biol. Toxicol., 1995, 11(1), 37-50.
65. Figg, W.D.; Raje, S.; Bauer, K.S.; Tompkins, A.; Venzon, D.; Bergan, R.; Chen, A.; Hamilton, M.; Pluda, J.; Reed, E. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci., 1999, 88(1), 121-5.
66. Jonsson, N.A. Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta. Pharm. Suec., 1972, 9(6), 521-42.
67. Ando, Y.; Price, D.K.; Dahut, W.L.; Cox, M.C.; Reed, E.; Figg, W.D. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol. Ther., 2002, 1(6), 669-73.
68. Ando, Y.; Fuse, E.; Figg, W.D. Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res., 2002, 8(6), 1964-73.
69. Lu, J.; Palmer, B.D.; Kestell, P.; Browett, P.; Baguley, B.C.; Muller, G.; Ching, L.M. Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 2003, 9(5), 1680-8.
70. Diggle, G.E. Thalidomide: 40 years on. Int. J. Clin. Pract., 2001, 55(9), 627-31.
71. Eriksson, T.; Bjorkman, S.; Hoglund, P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol., 2001, 57(5), 365-76.
72. Bosch, M.E.; Sanchez, A.J.; Rojas, F.S.; Ojeda, C.B. Recent advances in analytical determination of thalidomide and its metabolites. J. Pharm. Biomed. Anal., 2008, 46(1), 9-17.
73. Eriksson, T.; Bjorkman, S.; Roth, B.; Hoglund, P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol., 2000, 52(7), 807-17.
74. Hoglund, P.; Eriksson, T.; Bjorkman, S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm., 1998, 26(4), 363-83.
75. Blaschke, G.; Kraft, H.P.; Fickentscher, K.; Kohler, F. [Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers (author's transl)]. Arzneimittelforschung, 1979, 29(10), 1640-2.
76. Heger, W.; Schmahl, H.J.; Klug, S.; Felies, A.; Nau, H.; Merker, H.J.; Neubert, D. Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers. Teratog. Carcinog. Mutagen, 1994, 14(3), 115-22.
77. Yamamoto, T.; Shibata, N.; Sukeguchi, D.; Takashima, M.; Nakamura, S.; Toru, T.; Matsunaga, N.; Hara, H.; Tanaka, M.; Obata, T.; Sasaki, T. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg. Med. Chem. Lett., 2009, 19(14), 3973-6.
78. Yamamoto, T.; Shibata, N.; Takashima, M.; Nakamura, S.; Toru, T.; Matsunaga, N.; Hara, H. Enzymatic resolution and evaluation of enantiomers of cis-5′-hydroxythalidomide. Org. Biomol. Chem., 2008, 6(9), 1540-3.
79. Figg, W.D.; Hussain, M.H.; Gulley, J.L.; Arlen, P.M.; Aragon-Ching, J.B.; Petrylak, D.P.; Higano, C.S.; Steinberg, S.M.; Chatta, G.S.; Parnes, H.; Wright, J.J.; Sartor, O.; Dahut, W.L. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J. Urol., 2009, 181(3), 1104-13; discussion 1113.
80. Drake, M.J.; Robson, W.; Mehta, P.; Schofield, I.; Neal, D.E.; Leung, H.Y. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br. J. Cancer, 2003, 88(6), 822-7.
81. Sissung, T.M.; Baum, C.E.; Deeken, J.; Price, D.K.; Aragon-Ching, J.; Steinberg, S.M.; Dahut, W.; Sparreboom, A.; Figg, W.D. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res., 2008, 14(14), 4543-9.
82. Aragon-Ching, J.B.; Ning, Y.M.; Chen, C.C.; Latham, L.; Guadagnini, J.P.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Parnes, H.; Figg, W.D.; Dahut, W.L. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest., 2009, 27(2), 221-6.
83. Dahut, W.L.; Aragon-Ching, J.B.; Woo, S.; Tohnya, T.M.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Ventiz, J.; Figg, W.D. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J. Clin. Pharmacol., 2009, 49(6), 650-60.
84. Floissac, M.; Knight, R.; Levin, L.M.; Glode, E.D.; Crawford, E.D. Phase II Study of CC-4047 in Patients (pts) with Metastatic Hormone-Refractory Prostate Cancer (HRPC). J. Clin. Oncol., 2005, 23(16S, Part I of II), Abstract 4629.
85. Zhu, D.; Corral, L.G.; Fleming, Y.W.; Stein, B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother., 2008, 57(12), 1849-59.
86. Blansfield, J.A.; Caragacianu, D.; Alexander, H.R., 3rd; Tangrea, M.A.; Morita, S.Y.; Lorang, D.; Schafer, P.; Muller, G.; Stirling, D.; Royal, R.E.; Libutti, S.K. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin. Cancer Res., 2008, 14(1), 270-80.
87. Mangiameli, D.P.; Blansfield, J.A.; Kachala, S.; Lorang, D.; Schafer, P.H.; Muller, G.W.; Stirling, D.I.; Libutti, S.K. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J. Transl. Med., 2007, 538.
88. Wnendt, S.; Finkam, M.; Winter, W.; Ossig, J.; Raabe, G.; Zwingenberger, K. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality, 1996, 8(5), 390-6.
89. Chung, F.; Lu, J.; Palmer, B.D.; Kestell, P.; Browett, P.; Baguley, B.C.; Tingle, M.; Ching, L.M. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin. Cancer Res., 2004, 10(17), 5949-56.
90. Lepper, E.R.; Ng, S.S.; Gutschow, M.; Weiss, M.; Hauschildt, S.; Hecker, T.K.; Luzzio, F.A.; Eger, K.; Figg, W.D. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J. Med. Chem., 2004, 47(9), 2219-27.
91. Lu, J.; Helsby, N.; Palmer, B.D.; Tingle, M.; Baguley, B.C.; Kestell, P.; Ching, L.M. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J. Pharmacol. Exp. Ther., 2004, 310(2), 571-7.
92. Marks, M.G.; Shi, J.; Fry, M.O.; Xiao, Z.; Trzyna, M.; Pokala, V.; Ihnat, M.A.; Li, P.K. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol. Pharm. Bull., 2002, 25(5), 597-604.
93. Price, D.K.; Ando, Y.; Kruger, E.A.; Weiss, M.; Figg, W.D. 5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther. Drug Monit., 2002, 24(1), 104-10.
94. Inatsuki, S.; Noguchi, T.; Miyachi, H.; Oda, S.; Iguchi, T.; Kizaki, M.; Hashimoto, Y.; Kobayashi, H. Tubulin-polymerization inhibitors derived from thalidomide. Bioorg. Med. Chem. Lett., 2005, 15(2), 321-5.
95. Noguchi, T.; Fujimoto, H.; Sano, H.; Miyajima, A.; Miyachi, H.; Hashimoto, Y. Angiogenesis inhibitors derived from thalidomide. Bioorg. Med. Chem. Lett., 2005, 15(24), 5509-13.